NZ592363A - Anti cxcr4 antibodies and their use for the treatment of cancer - Google Patents

Anti cxcr4 antibodies and their use for the treatment of cancer

Info

Publication number
NZ592363A
NZ592363A NZ592363A NZ59236309A NZ592363A NZ 592363 A NZ592363 A NZ 592363A NZ 592363 A NZ592363 A NZ 592363A NZ 59236309 A NZ59236309 A NZ 59236309A NZ 592363 A NZ592363 A NZ 592363A
Authority
NZ
New Zealand
Prior art keywords
antibodies
cxcr4
selecting
cancer
treatment
Prior art date
Application number
NZ592363A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Veronique Grenier-Caussanel
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NZ592363A publication Critical patent/NZ592363A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
NZ592363A 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer NZ592363A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ592363A true NZ592363A (en) 2012-08-31

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592363A NZ592363A (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Country Status (28)

Country Link
US (4) US8557964B2 (enExample)
EP (2) EP2172485A1 (enExample)
JP (1) JP5723279B2 (enExample)
KR (1) KR101671039B1 (enExample)
CN (1) CN102209730B (enExample)
AR (1) AR073748A1 (enExample)
AU (1) AU2009299787B2 (enExample)
BR (1) BRPI0920531A2 (enExample)
CA (1) CA2738782C (enExample)
CL (1) CL2011000730A1 (enExample)
CY (1) CY1115572T1 (enExample)
DK (1) DK2342233T3 (enExample)
ES (1) ES2503732T3 (enExample)
GE (1) GEP20146084B (enExample)
HR (1) HRP20140899T1 (enExample)
IL (1) IL212066A (enExample)
MA (1) MA32928B1 (enExample)
MX (1) MX2011003509A (enExample)
NZ (1) NZ592363A (enExample)
PL (1) PL2342233T3 (enExample)
PT (1) PT2342233E (enExample)
RS (1) RS53578B1 (enExample)
RU (1) RU2573897C2 (enExample)
SI (1) SI2342233T1 (enExample)
TW (1) TWI469792B (enExample)
UA (1) UA102867C2 (enExample)
WO (1) WO2010037831A1 (enExample)
ZA (1) ZA201102969B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Ｈｉｖの治療用抗体
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
MX371455B (es) * 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
AU2014324102B2 (en) * 2013-09-23 2021-01-28 Wilson Wolf Manufacturing, LLC Improved methods of genetically modifying animal cells
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
US10514670B2 (en) * 2016-05-25 2019-12-24 Kabushiki Kaisha Toshiba Energy management apparatus, management system, power consumption monitoring method and program
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN112513079A (zh) 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
EP4771050A1 (en) * 2023-08-28 2026-07-08 Regeneron Pharmaceuticals, Inc. Anti-cxcr4 antibodies and uses thereof
CN117003876B (zh) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2006086883A1 (en) * 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP2297206A1 (en) * 2008-05-14 2011-03-23 Eli Lilly And Company Anti-cxcr4 antibodies

Also Published As

Publication number Publication date
DK2342233T3 (da) 2014-09-29
CA2738782C (en) 2017-11-28
HRP20140899T1 (hr) 2014-11-07
TW201018483A (en) 2010-05-16
KR101671039B1 (ko) 2016-11-01
JP5723279B2 (ja) 2015-05-27
EP2172485A1 (en) 2010-04-07
IL212066A (en) 2015-05-31
GEP20146084B (en) 2014-05-13
JP2012504401A (ja) 2012-02-23
AU2009299787A1 (en) 2010-04-08
RU2573897C2 (ru) 2016-01-27
PT2342233E (pt) 2014-10-03
CA2738782A1 (en) 2010-04-08
RS53578B1 (sr) 2015-02-27
IL212066A0 (en) 2011-06-30
US20140050661A1 (en) 2014-02-20
MA32928B1 (fr) 2012-01-02
CN102209730B (zh) 2014-11-05
US20110294156A1 (en) 2011-12-01
ES2503732T3 (es) 2014-10-07
US20110287451A1 (en) 2011-11-24
AU2009299787A2 (en) 2011-06-02
AU2009299787B2 (en) 2015-06-18
MX2011003509A (es) 2011-05-02
RU2011115559A (ru) 2012-11-10
US8557964B2 (en) 2013-10-15
US20110020218A1 (en) 2011-01-27
SI2342233T1 (sl) 2014-10-30
CL2011000730A1 (es) 2012-02-03
AR073748A1 (es) 2010-12-01
CY1115572T1 (el) 2017-01-04
TWI469792B (zh) 2015-01-21
HK1163119A1 (en) 2012-09-07
US9388248B2 (en) 2016-07-12
PL2342233T3 (pl) 2014-11-28
EP2342233B1 (en) 2014-06-25
UA102867C2 (uk) 2013-08-27
EP2342233A1 (en) 2011-07-13
ZA201102969B (en) 2011-12-28
KR20110081229A (ko) 2011-07-13
CN102209730A (zh) 2011-10-05
WO2010037831A1 (en) 2010-04-08
BRPI0920531A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CR20200459A (es) Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
WO2018151836A8 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
NO20084480L (no) Diaryltiohydantoin forbindelser
IL258880A (en) Diarylhydantoin compounds
EA201100340A1 (ru) Человеческие антитела, связывающие ген активатор лимфоцитов-3 (lag-3), и их применение
NO20091841L (no) Antistoffer mot lymfotoksin-alfa
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
MY150984A (en) Anti-agf antibodies
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
NZ593964A (en) Human anti-alpha-synuclein autoantibodies
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
NZ599971A (en) Monoclonal antibodies to progastrin and their uses
IN2012DN05101A (enExample)
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
TW200626900A (en) Wnt proteins and detection and treatment of cancer
IL193479A0 (en) Modulators of muscarinic receptors
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
WO2010004438A3 (en) Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 OCT 2016 BY ACUMASS

Effective date: 20130930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2017 BY ACUMASS

Effective date: 20160920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2018 BY ACUMASS

Effective date: 20170926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2019 BY ACUMASS

Effective date: 20180918

LAPS Patent lapsed